Mercer Global Advisors Inc. ADV Grows Stock Holdings in Humana Inc. (NYSE:HUM)

Mercer Global Advisors Inc. ADV lifted its stake in shares of Humana Inc. (NYSE:HUM) by 30.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,630 shares of the insurance provider’s stock after purchasing an additional 2,021 shares during the period. Mercer Global Advisors Inc. ADV’s holdings in Humana were worth $3,224,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in HUM. CarsonAllaria Wealth Management Ltd. grew its holdings in Humana by 111.4% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after buying an additional 39 shares in the last quarter. Hantz Financial Services Inc. acquired a new position in shares of Humana during the 2nd quarter valued at about $35,000. Family Firm Inc. purchased a new stake in shares of Humana in the second quarter valued at about $37,000. Carolinas Wealth Consulting LLC increased its position in Humana by 274.1% during the fourth quarter. Carolinas Wealth Consulting LLC now owns 101 shares of the insurance provider’s stock worth $46,000 after purchasing an additional 74 shares during the last quarter. Finally, Riverview Trust Co purchased a new position in Humana during the second quarter worth about $44,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Price Performance

HUM stock opened at $310.41 on Monday. The business’s 50-day moving average is $357.71 and its two-hundred day moving average is $345.60. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.66 and a quick ratio of 1.66. The firm has a market capitalization of $37.40 billion, a P/E ratio of 19.33, a P/E/G ratio of 2.56 and a beta of 0.50. Humana Inc. has a 1 year low of $298.61 and a 1 year high of $530.54.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share for the quarter, beating the consensus estimate of $5.89 by $1.07. Humana had a net margin of 1.53% and a return on equity of 16.12%. The firm had revenue of $29.54 billion for the quarter, compared to analysts’ expectations of $28.52 billion. During the same quarter last year, the company earned $8.94 earnings per share. The firm’s revenue was up 10.4% compared to the same quarter last year. Analysts anticipate that Humana Inc. will post 16 earnings per share for the current fiscal year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Monday, September 30th will be paid a dividend of $0.885 per share. The ex-dividend date is Monday, September 30th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.14%. Humana’s payout ratio is currently 22.04%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on HUM. TD Cowen increased their price target on shares of Humana from $396.00 to $407.00 and gave the company a “buy” rating in a research note on Wednesday, July 24th. Truist Financial increased their price objective on Humana from $355.00 to $400.00 and gave the stock a “hold” rating in a research report on Monday, July 15th. JPMorgan Chase & Co. lifted their target price on Humana from $332.00 to $396.00 and gave the company a “neutral” rating in a research report on Wednesday, August 21st. Oppenheimer increased their price target on Humana from $370.00 to $400.00 and gave the stock an “outperform” rating in a report on Thursday, August 1st. Finally, Deutsche Bank Aktiengesellschaft upped their target price on shares of Humana from $341.00 to $349.00 and gave the company a “hold” rating in a research report on Friday, August 2nd. Thirteen investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $398.70.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.